MedTrace Logo

Pazopanib in Second-line Therapy in Renal Cell Carcinoma

NCT01577784 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2014-03-12

No results posted yet for this study

Summary

The principal aim of the study is to determine the objective response rate that offers the second-line treatment with pazopanib in patients with carcinoma of advanced renal cells that have progressed or that have not tolerated the first line of treatment with a Tyrosine Kinase Inhibitor. The secondary aims are to determine the overall survival and the treatment safety profile for these patients in second-line treatment with pazopanib. The exploratory aim is to determine the correlation between biomarkers in patient blood and tumor samples, and the clinical results obtained with pazopanib.

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

Pazopanib

800 mg / day of pazopanib in monotherapy.

Sponsors & Collaborators

  • Trial Form Support S.L.

    collaborator OTHER

  • Associació per a la Recerca Oncologica, Spain

    lead OTHER

Principal Investigators

  • Joaquim Bellmunt, MD · Hospital del Mar

  • Marta Guix, MD · Hospital del Mar

  • Juan Manuel Sepúlveda, MD · Hospital 12 de Octubre

  • Enrique Gallardo, MD · Corporació Sanitaria Parc Taulí

  • Xavier García del Muro, MD · Hospital Universitari de Bellvitge

  • Olatz Etxaniz, MD · Germans Trias i Pujol Hospital

  • José Luis González Larriba, MD · Hospital San Carlos, Madrid

  • Jose Angel Arranz, MD · Hospital General Universitario Gregorio Marañón

  • Emilio Esteban, MD · Hospital Universitario Central de Asturias

  • Aranzazu González del Alba, MD · Hospital Son Espases

  • Pablo Maroto, MD · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2014-10-31
Completion
2015-10-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01577784 on ClinicalTrials.gov